Citations

Clear

499 citation(s) found for "Tracy, PB".

Patient perceptions and use of non‐statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry
Lowenstern, Angela , Li, Shuang , Návar, Ann Marie , Virani, Salim S. , Roger, Véronique L. , Robinson, Jennifer G. , Goldberg, Anne C. , Kampman, Wendy, Wang, Tracy Y., Navar, Ann Marie , Peterson, Eric D.

Mayo Clinic

Clinical Cardiology | May 19, 2021 | Volume: 44 | Issue: 6 | Pages: 863-870

10.1002/clc.23625 | PMID 34008247 Get It

AbstractBackgroundNon‐statin lipid lowering therapies (LLTs) provide additional treatment options for patients. Use patterns and patient perceptions of non‐statin LLT remain incompletely described.HypothesisThe guideline‐recommended statin intensity remains underutilized in patients treated with and without non‐statin LLT.MethodsThe PALM Registry collected LLT information on patients with or at risk of ASCVD treated at 125 US clinics in 2015. We compared patient perceptions, lipid levels and statin use among patients treated with and without non‐statin LLT.ResultsAmong 7720 patients, 1930 (25.0%) were treated with a non‐statin LLT (1249 fish oil, 417 fibrates, 329 ezetimibe, 196 niacin). Concurrent statin treatment occurred in 73.7%, of which 45.4% were dosed under the guideline‐recommended intensity. Compared with patients on statin alone, patients receiving both a statin and non‐statin LLT (n = 1423) were more likely to be male, white race and to perceive themselves as higher risk of ASCVD compared with their peers (38.5% vs. 34.9%, p = .047). Only 27.4% of patients treated with non‐statin LLT alone perceived themselves at higher risk. Most (75.7%) patients treated with a non‐statin LLT alone reported never being treated with a statin, despite ASCVD in 30.8% of these patients. Among those previously treated with a statin, 59.3% reported being willing to try a statin again.ConclusionsNon‐statin LLT is used in one in four patients with or at risk for ASCVD; its use is frequently in place of statin therapy or in the absence of guideline‐recommended statin intensity. More work is needed to establish statins as first line therapy.
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
Han, Se young, Mrózek, Krzysztof , Morgan, Elizabeth A. , Vestergaard, Hanne , Ohgami, Robert S. , Kluin, Philip M., Kristensen, Thomas Kielsgaard , Pullarkat, Sheeja T. , Møller, Michael , Kim, Young , Czuchlewski, David R., Hilberink, Jacobien R. , Horny, Hans-Peter, Dolan, Michelle, Ku, Nam K., Yi, Cecilia Arana , Pullarkat, Vinod , Kohlschmidt, Jessica, Salhotra, Amandeep , Soma, Lori , Bloomfield, Clara D. , Chen, Dong , Sperr, Wolfgang R. , Marcucci, Guido , Cho, Christina , Broesby‐Olsen, Sigurd , Larson, Melissa L., Deeg, H. Joachim , Hoermann, Gregor , Litzow, Mark R. , Nakamura, Ryotaro , Weisdorf, Daniel J. , Huls, Gerwin , Valent, Peter , Üstün, Celalettin , Morgan, Elizabeth A , Vestergaard, Hanne , Møller, Michael Boe , Schiefer, Ana-Iris , Hilberink, Jacobien R , Arana Yi, Cecilia , Deeg, H Joachim , Perales, Miguel-Angel , Litzow, Mark R. , Nakamura, Ryotaro , Weisdorf, Dan , Valent, Peter , Ustun, Celalettin , Yeung, Cecilia , Chen, Dong , Sperr, Wolfgang , Voutsinas, Jenna M. , Wu, Qian Vicky , Baughn, Linda B. , George, Tracy I. , Akin, Cem , Gotlib, Jason , Linden, Michael A. , Perales, Miguel‐Angel , Hornick, Jason L. , Borthakur, Gautam , Yeung, Cecilia C.S.

Mayo Clinic

Blood Advances | May 18, 2021 | Volume: 5 | Issue: 10 | Pages: 2481-2489

10.1182/bloodadvances.2020003605 | PMID 34003250 Get It

Abstract Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, ∼40% of patients relapse, and the literature suggests that patients with inv(16) fare differently from those with t(8;21). We retrospectively analyzed 537 patients with CBF-AML, focusing on additional cytogenetic aberrations to examine their impact on clinical outcomes. Trisomies of chromosomes 8, 21, or 22 were significantly more common in patients with inv(16)/t(16;16): 16% vs 7%, 6% vs 0%, and 17% vs 0%, respectively. In contrast, del(9q) and loss of a sex chromosome were more frequent in patients with t(8;21): 15% vs 0.4% for del(9q), 37% vs 0% for loss of X in females, and 44% vs 5% for loss of Y in males. Hyperdiploidy was more frequent in patients with inv(16) (25% vs 9%, whereas hypodiploidy was more frequent in patients with t(8;21) (37% vs 3%. In multivariable analyses (adjusted for age, white blood counts at diagnosis, and KIT mutation status), trisomy 8 was associated with improved overall survival (OS) in inv(16), whereas the presence of other chromosomal abnormalities (not trisomy 8) was associated with decreased OS. In patients with t(8;21), hypodiploidy was associated with improved disease-free survival; hyperdiploidy and del(9q) were associated with improved OS. KIT mutation (either positive or not tested, compared with negative) conferred poor prognoses in univariate analysis only in patients with t(8;21).
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1
Frishberg, Yaacov, Groothoff, Jaap W. , Hulton, Sally‐Anne, Magen, Daniella , Harambat, Jérôme, Hoff, William G. van’t, Lorch, Ulrike , Milliner, Dawn S. , Haslett, Patrick , Garg, Pushkal, Vaishnaw, Akshay, Talamudupula, Sandeep, Lu, Jiandong , Habtemariam, Bahru, Erbe, David V., McGregor, Tracy L., Cochat, Pierre , collaborators, on behalf of the study, Garrelfs, Sander F. , Magen, Daniella , Deschênes, Georges , Harambat, Jérôme , Lieske, John C. , collaborators, on behalf of the study

Mayo Clinic

Clinical Journal of the American Society of Nephrology | May 13, 2021 | Volume: 16 | Issue: 7 | Pages: 1025-1036

10.2215/cjn.14730920 | PMID 33985991 Get It

Background and objectives In the rare disease primary hyperoxaluria type 1, overproduction of oxalate by the liver causes kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production. The objective of this first-in-human, randomized, placebo-controlled trial was to evaluate the safety, pharmacokinetic, and pharmacodynamic profiles of lumasiran in healthy participants and patients with primary hyperoxaluria type 1. Design, setting, participants, & measurements This phase 1/2 study was conducted in two parts. In part A, healthy adults randomized 3:1 received a single subcutaneous dose of lumasiran or placebo in ascending dose groups (0.3–6 mg/kg). In part B, patients with primary hyperoxaluria type 1 randomized 3:1 received up to three doses of lumasiran or placebo in cohorts of 1 or 3 mg/kg monthly or 3 mg/kg quarterly. Patients initially assigned to placebo crossed over to lumasiran on day 85. The primary outcome was incidence of adverse events. Secondary outcomes included pharmacokinetic and pharmacodynamic parameters, including measures of oxalate in patients with primary hyperoxaluria type 1. Data were analyzed using descriptive statistics. Results Thirty-two healthy participants and 20 adult and pediatric patients with primary hyperoxaluria type 1 were enrolled. Lumasiran had an acceptable safety profile, with no serious adverse events or study discontinuations attributed to treatment. In part A, increases in mean plasma glycolate concentration, a measure of target engagement, were observed in healthy participants. In part B, patients with primary hyperoxaluria type 1 had a mean maximal reduction from baseline of 75% across dosing cohorts in 24-hour urinary oxalate excretion. All patients achieved urinary oxalate levels ≤1.5 times the upper limit of normal. Conclusions Lumasiran had an acceptable safety profile and reduced urinary oxalate excretion in all patients with primary hyperoxaluria type 1 to near-normal levels. Clinical Trial registry name and registration number: Study of Lumasiran in Healthy Adults and Patients with Primary Hyperoxaluria Type 1, NCT02706886
Relationship Between Rheumatoid Arthritis and Pulmonary Function Measures on Spirometry in the UK Biobank
Prisco, Lauren, Wang, Jiaqi , Hobbs, Brian D. , Huang, Weixing , Martin, Lily W., Kronzer, Vanessa L. , Huang, Sicong , Silverman, Edwin K. , Doyle, Tracy J. , Sparks, Jeffrey A. , Kronzer, Vanessa L , Huang, Sicong , Sparks, Jeffrey A , Hobbs, Brian D , Moll, Matthew , Cho, Michael H.

Mayo Clinic

Arthritis & Rheumatology | May 13, 2021 | Volume: 73 | Issue: 11 | Pages: 1994-2002

10.1002/art.41791 | PMID 33982900 Get It

ObjectiveTo investigate the independent relationship of rheumatoid arthritis (RA) to the type and severity of pulmonary patterns on spirometry compared to the pulmonary patterns in general population controls.MethodsIn this cross‐sectional study, we investigated the association of RA with pulmonary function measures on spirometry among subjects in the UK Biobank who underwent spirometry for research purposes. RA cases were identified based on self‐report and current disease‐modifying antirheumatic drug/glucocorticoid use. Controls were subjects without RA from the general population. Outcome measures included continuous forced expiratory volume in 1 second percent predicted (FEV1%) and forced vital capacity percent predicted (FVC%), type of spirometric pattern (restrictive or obstructive), and severity of the restrictive or obstructive pattern. We used multivariable regression to estimate the effects in RA cases compared to the effects in controls, adjusting for age, sex, body mass index, and smoking status/pack‐years.ResultsAmong 350,776 analyzed subjects who underwent spirometry (mean age 56.3 years; 55.8% female; 45.5% ever smokers), we identified 2,008 cases of treated RA. In multivariable analyses, RA was associated with lower FEV1% (β = –2.93 [95% confidence interval (95% CI) –3.63, –2.24]), FVC% (β = –2.08 [95% CI –2.72, –1.45]), and FEV1/FVC (β = –0.008 [95% CI –0.010, –0.005]) compared to controls. RA was additionally associated with restrictive patterns (odds ratio [OR] 1.36 [95% CI 1.21, 1.52]) and obstructive patterns (OR 1.21 [95% CI 1.07, 1.37]) independent of confounders, and was most strongly associated with severe restrictive and obstructive patterns.ConclusionRA is associated with increased odds of restrictive and obstructive patterns, and this relationship is not explained by confounders, including smoking status. In addition to restrictive lung disease, clinicians should also be aware that airway obstruction may be a pulmonary manifestation of RA.
DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma
Yang, Ju Dong , Ghoz, Hassan , Aboelsoud, Mohammed M., Yab, Tracy C. , Cao, Xiaoming , Giama, Nasra H., Moser, Catherine D., Smyrk, Thomas C. , Kipp, Benjamin R. , Roberts, Lewis R. , Berger, Calise K. , Foote, Patrick H. , Barr Fritcher, Emily G, Mahoney, Douglas W. , Kisiel, John B , Roberts, Lewis R , Yang, Ju Dong , Taylor, William R. , Fritcher, Emily G. Barr , Gores, Gregory J. , Kisiel, John B.

Mayo Clinic

Hepatology Communications | May 3, 2021 | Volume: 5 | Issue: 8 | Pages: 1448-1459

10.1002/hep4.1730 | PMID 34430788 Get It

Cholangiocarcinoma (CCA) has poor prognosis due to late‐stage, symptomatic presentation. Altered DNA methylation markers may improve diagnosis of CCA. Reduced‐representation bisulfite sequencing was performed on DNA extracted from frozen CCA tissues and matched to adjacent benign biliary epithelia or liver parenchyma. Methylated DNA markers (MDMs) identified from sequenced differentially methylated regions were selected for biological validation on DNA from independent formalin‐fixed, paraffin‐embedded CCA tumors and adjacent hepatobiliary control tissues using methylation‐specific polymerase chain reaction. Selected MDMs were then blindly assayed on DNA extracted from independent archival biliary brushing specimens, including 12 perihilar cholangiocarcinoma, 4 distal cholangiocarcinoma cases, and 18 controls. Next, MDMs were blindly assayed on plasma DNA from patients with extrahepatic CCA (eCCA), including 54 perihilar CCA and 5 distal CCA cases and 95 healthy and 22 primary sclerosing cholangitis controls, balanced for age and sex. From more than 3,600 MDMs discovered in frozen tissues, 39 were tested in independent samples. In the clinical pilot of 16 MDMs on cytology brushings, methylated EMX1 (empty spiracles homeobox 1) had an area under the curve (AUC) of 0.98 (95% confidence interval [CI], 0.95‐1.0). In the clinical pilot on plasma, a cross‐validated recursive partitioning tree prediction model from nine MDMs was accurate for de novo eCCA (AUC, 0.88 [0.81‐0.95]) but not for primary sclerosing cholangitis–associated eCCA (AUC, 0.54 [0.35‐0.73]). Conclusion : Next‐generation DNA sequencing yielded highly discriminant methylation markers for CCA. Confirmation of these findings in independent tissues, cytology brushings, and plasma supports further development of DNA methylation to augment diagnosis of CCA.
Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study
MacDonald, David M. , Collins, Gary, Wendt, Chris H., Wolfson, Julian, Tracy, Russell P., Rhame, Frank, Deeks, Steven, Rizza, Stacey A., Temesgen, Zelalem, Morse, Caryn, Liappis, Angelike P., Sereti, Irini, Baker, Jason V., Kunisaki, Ken M., Baker, Jason V. , Wendt, Chris H. , Kunisaki, Ken M. , Wendt, Chris H , Wolfson, Julian , Kunisaki, Ken M , MacDonald, David M. , Collins, Gary, Wolfson, Julian , Tracy, Russell P., Rhame, Frank, Deeks, Steven, Rizza, Stacey A., Temesgen, Zelalem, Morse, Caryn, Liappis, Angelike P., Sereti, Irini, Baker, Jason V.

Mayo Clinic

AIDS Research and Human Retroviruses | March 22, 2021 | Volume: 38 | Issue: 2 | Pages: 127-130

10.1089/aid.2020.0285 | PMID 33749317 Get It

HIV is an independent risk factor for lung disease, including chronic obstructive pulmonary disease (COPD) and emphysema. Angiotensin receptor blockers may be beneficial in COPD and emphysema through pathways that have been implicated in HIV-related lung disease. We performed a randomized comparison of the effects of losartan versus placebo on the plasma concentrations of the pneumoproteins, surfactant protein D (SPD) and club cell secretory protein (CCSP), in people living with HIV (PLWH). A total of 108 PLWH were included (52 assigned to losartan and 56 assigned to placebo). We found no difference in the change from baseline in log 2 concentrations of CCSP or SPD over 1 year of follow-up. For SPD, we found a strong interaction by CD4+ counts, where those with CD4+ counts >350 cells/mm 3 treated with losartan had more reduction (improvement) in SPD concentration than those treated with placebo ( p value for interaction <.001). In conclusion, we did not find a beneficial effect of losartan on pneumoprotein concentrations in PLWH, but PLWH with higher CD4+ counts may have improvement in SPD when treated with losartan.
Bedside Diffuse Optical Tomography of Disrupted Brain Connectivity During Acute Stroke
Burke, Broc , Bergonzi, Karla M. , Sherafati, Arefeh , Fishell, Andrew K., Burns‐Yocum, Tracy M. , Culver, Joseph P., Ferradal, Silvina L. , Palanca, Ben Julian A. , Dhar, Rajat , Kumar, Gyanendra , Lee, Jin‐Moo , Eggebrecht, Adam T.

Mayo Clinic

No container title available | March 17, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-107369/v1 Get It

Abstract Neurological instability during the first days following ischemic stroke reflects the potential to salvage brain tissue at risk for infarct growth, hemorrhagic transformation, or malignant edema. However, current clinical care provides intermittent assessments on the order of at least an hour apart potentially missing the early detection of neurological deterioration. Optical imaging offers a continuous, portable alternative to the current combination of physical exams and radiological imaging. However, optical imaging technology has heretofore lacked the crucial combination of portability, resolution, and coverage required for assessing distributed brain function. Here, we present a portable high-density diffuse optical tomography (HD-DOT) system that overcomes these limitations to assess neurological disruption at the bedside. We imaged patients within 72 hours after ischemic stroke onset and demonstrate that HD-DOT is sensitive to both the presence of stoke (Cohen’s d = 1.5, p = 1.2 × 10− 3) as well as the degree of neurological disruption measured by NIH Stroke Scale (R2 = 0.69, p = 4.7 × 10− 4).
Systematic review of outcomes and endpoints in acute migraine clinical trials
McGinley, James S., Nishida, Tracy K., Buse, Dawn C. , Goadsby, Peter J. , Goadsby, Peter J , Houts, Carrie R. , Wirth, Robert J. , Dodick, David W. , Lipton, Richard B.

Mayo Clinic

Headache: The Journal of Head and Face Pain | February 21, 2021 | Volume: 61 | Issue: 2 | Pages: 263-275

10.1111/head.14067 | PMID 33611818 Get It

Abstract Background/Objective To review the acute migraine clinical trial literature and provide a summary of the endpoints and outcomes used in such trials. Method A systematic literature review, following a prespecified (but unregistered) protocol developed to adhere to recommendations of the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses, was conducted to understand endpoints and outcomes used in acute migraine clinical trials. Predefined terms were searched in PubMed to locate clinical trials assessing acute migraine treatments. Final database search was conducted on October 28, 2019. Identified publications were reviewed against established inclusion and exclusion criteria to determine eligibility. Data related to general trial design characteristics, sample characteristics, and outcomes and endpoints reported in each publication were extracted from eligible publications. Descriptive summaries of design features, sample characteristics, and the endpoints and outcomes employed across publications were constructed. Outcomes are presented within four broad categories: (a) pain‐related outcomes (pain relief, pain freedom, etc.), (b) associated symptoms (nausea, photophobia, etc.), (c) disability/impairment/impact, (d) patient‐reported outcome measures (PROMs, general health and migraine/headache‐specific). Endpoint types were categorized within three broad categories: (a) change from baseline, (b) fixed timepoint, and (c) responder definitions (e.g., 50% reduction). This review focuses on a subset of recent (1998 or later) randomized and blinded publications evaluating drugs or medical devices. Results Of 1567 publications found through the initial search and reference section reviews, 705 met criteria and were included for data extraction. Inter‐rater agreement kappas for the descriptive variables extracted had an average kappa estimate of 0.86. The more recent, randomized and blinded pharmaceutical and medical device article subset includes 451 publications (451/705, 63.9%). The outcomes and endpoints varied substantially across trials, ranging from pain relief or freedom, freedom from or relief of migraine‐associated symptoms, use of acute or rescue medication, and various other PROMs, including measures of satisfaction and quality of life. Within the recent randomized and blinded article subset, most articles examined ≥1 pain‐related outcome (430/451, 95.3%). Of the publications that examined pain, outcomes most often used were pain relief (310/430, 72.1%), pain freedom (279/430, 64.9%), and headache recurrence (202/43,051, 47.0%) or rescue medication use (278/430, 64.9%). Associated symptoms such as nausea, photophobia, and phonophobia were more frequently measured (299/451, 66.3%) compared to most bothersome associated symptom (16/451, 3.5%), as it is a new addition to regulatory guidance. Over one‐third of eligible publications examined disability/impairment (186/451, 41.2%) or ≥1 PROM (159/451, 35.3%). The definition of the endpoints used (e.g., change from baseline, fixed timepoint comparisons, categorization of “responders” to treatment based on wide variety of “responder definitions”) also differed substantially across publications. Conclusion Acute migraine clinical trials exhibit a large amount of variability in outcomes and endpoints used, in addition to the variability in how outcomes and endpoints were used from trial‐to‐trial. There were some common elements across trials that align with guidance from the International Headache Society, the Food and Drug Administration and other regulatory agencies (e.g., assessing pain and associated symptoms, 2‐hour post‐treatment). Other aspects of acute migraine clinical trial design did not follow guidance. For example, multi‐item PROMs intended to measure constructs (e.g., scales) are rarely used, the use of pain‐related outcomes is inconsistent, some associated symptom assessments are idiosyncratic, and the timing of the assessment of primary endpoints is variable. The development of a core set of outcomes and endpoints for acute migraine clinical trials that are patient‐centered and statistically robust could improve the conduct of individual trials, facilitate cross‐trial comparisons, and better support informed treatment decisions by healthcare professionals and patients.
Systematic review of outcomes and endpoints in preventive migraine clinical trials
McGinley, James S., Nishida, Tracy K., Buse, Dawn C. , Goadsby, Peter J. , Goadsby, Peter J , Houts, Carrie R. , Lipton, Richard B. , Dodick, David W. , Wirth, Robert J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | February 20, 2021 | Volume: 61 | Issue: 2 | Pages: 253-262

10.1111/head.14069 | PMID 33600610 Get It

Abstract Background Over the last six decades (earliest included publication from 1959), clinical trials of migraine preventive treatments have led to the regulatory approval of many medications and devices. Despite similar clinical goals, the outcomes and endpoints used in these trials are broad and not well standardized. Objective To describe results from a systematic literature review focused on outcomes and endpoints used in preventive migraine clinical trials. Method A systematic literature review, following a pre‐specified (unregistered) protocol developed to adhere to recommendations of the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses, was conducted to characterize the endpoints and outcomes used in preventive migraine clinical trials. Predetermined terms were searched in PubMed on October 28, 2019. Data related to trial design, subject characteristics, outcomes, and endpoints reported in each publication were extracted. Descriptive summaries of these features were tabulated for the recent subset of publications, published during or after 1988, that were randomized, blinded, and focused on pharmacological or device therapies for the preventive treatment of migraine. Results The initial literature search identified 1506 publications, of which 757 publications were eligible for data extraction. Of specific clinical interest were the recent subset of 268 articles (268/757, 35.4%) fulfilling the targeted criteria. Results showed that the outcomes used to define endpoints varied substantially across publications. For example, in the recent subset of publications, 68.7% (184/268) of the publications examined ≥1 migraine‐specific outcome, 39.6% (106/268) examined ≥1 headache‐specific outcome, 50.7% (136/268) examined ≥1 acute/rescue medication use outcome, 40.3% (108/268) examined ≥1 headache‐related patient‐reported outcome measure (PROM), and 22.0% (59/268) examined ≥1 non‐headache‐specific PROM. Furthermore, the definition of the endpoints used (e.g., change from baseline, fixed timepoint comparisons, categorization of “responders” to treatment based on wide variety of “responder definitions”) also differed across publications. Conclusion Publications from clinical trials of preventive migraine pharmacologic and device treatments differed in terms of study design, endpoint definitions, and how endpoints and outcomes were measured. Although there were common outcomes and endpoints used across publications, no clear “standardized” set of endpoints and outcomes emerged. The inconsistencies in endpoints and outcomes within this literature suggest that the development of a uniform set of outcomes and endpoints could improve the clinical meaningfulness of clinical trial results, facilitate cross‐trial comparisons and better inform patient care. This standard set of outcomes and endpoints should be statistically robust and informed by the priorities of various stakeholders, most importantly, the needs and preferences of people living with migraine.